NCT06329869 - Sacituzumab Govitecan for Advanced Esophageal Squamous Cell Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2027

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

DRUG

Sacituzumab govitecan

Sacituzumab govitecan, 10 mg/kg intravenous infusion (the first infusion is to be administered over 3 hours; subsequent infusions may be administered over 1 to 2 hours if previous infusions were well tolerated) on day 1 and 8 of 21-day cycle.

Trial Locations (1)

Unknown

RECRUITING

National Taiwan University Hospital, Taipei